Finally, after IFNb treatment, measuring heart rate8 [80] and triplet testing of Caspase 2, Apoptosis-Related Cysteine Peptidase (CASP2), Interleukin 10 (IL10), and Interleukin 12 Receptor Subunit Beta 1 (IL12Rb1) [75] were the strongest predictors for response to MS treatments. This evidence concerns the gene CASP2 and myeloid sarcoma.